DEERFIELD, Ill., March 19 /PRNewswire/ -- Takeda Pharmaceuticals North America, Inc. today announced proposed new leadership for Takeda America Holdings, Inc. (TAH), Takeda Pharmaceuticals North America, Inc. (TPNA) and Takeda Global Research & Development Center, Inc. (TGRD) following an earlier announcement related to Takeda’s plans to conclude its joint venture in the United States, TAP Pharmaceutical Products Inc. (TAP).
Effective at the close of the TAP transaction, Takeda Pharmaceuticals North America, Inc. and Takeda Global Research & Development Center, Inc. will report to Takeda America Holdings, Inc. Alan MacKenzie, the current president of TAP and a former president of Takeda Pharmaceuticals North America, Inc. has been named executive vice president of Takeda America Holdings.
MacKenzie will also serve as CEO of Takeda Pharmaceuticals North America, Inc. in addition to his role as executive vice president of Takeda America Holdings.
Mark Booth, current president of Takeda Pharmaceuticals North America, Inc., will continue to lead the company until the TAP transaction is closed and has agreed to continue on with the company for some period thereafter to support integration activities.
Reporting to MacKenzie as president of Takeda Global Research & Development Center, Inc. will be Nancy Joseph-Ridge, M.D., currently TAP’s vice president of research and development. Dr. Joseph-Ridge will also assume her position effective the close of the TAP transaction.
“I have great confidence in Takeda’s proposed new leadership for the United States, an important market for Takeda’s global growth plans,” said Yasuchika Hasegawa, president, Takeda Pharmaceutical Company Limited. “Alan MacKenzie not only helped launch both TPNA and its first product, Actos, he has been instrumental in helping create success at Takeda companies for more than 22 years. Dr. Nancy Joseph-Ridge is a well-known and highly respected physician, researcher and strong leader with an unwavering commitment to scientific excellence. I would also like to take this opportunity to thank Mark Booth for his many contributions to Takeda and wish him well in his future endeavors.”
MacKenzie first joined TAP as a sales representative in 1985 and served in various senior-level roles for TAP, including vice president of sales and director of marketing. He holds a B.S.N. from Wagner College, a B.A. in economics from City University of New York, and a M.B.A. from the University of Chicago.
Prior to joining TAP in 2002, Dr. Joseph-Ridge worked for Searle, which later became part of Pfizer, in drug safety and clinical development. She previously held clinical and academic roles in Chicago at Rush-Presbyterian-St. Luke’s Medical Center and the University of Chicago Hospitals. She received her M.D. from the University of Illinois at Chicago.
Takeda Pharmaceuticals North America, Inc.
Based in Deerfield, Ill., Takeda Pharmaceuticals North America, Inc. is a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, the largest pharmaceutical company in Japan. In the United States, Takeda currently markets products for diabetes, insomnia, wakefulness and gastroenterology. Through the Takeda Global Research & Development Center, Inc. the company has a robust pipeline with compounds in development for diabetes, cardiovascular disease and other conditions. Takeda is committed to striving toward better health for individuals and progress in medicine by developing superior pharmaceutical products. To learn more about the company and its products, visit http://www.tpna.com.
CONTACT: Matt Kuhn of Takeda Pharmaceuticals North America,
+1-224-554-5609, mkuhn@tpna.com
Web site: http://www.tpna.com/
